Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib plus Sintilimab in advanced endometrial cancer
NCT06584032Phase 3Recruiting
- Sponsor
- HUTCHMED
- Start
- Dec 2024
- Primary completion
- Jan 2029
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of fruquintinib in endometrial cancer (EC), sponsored by HUTCHMED. Started Dec 2024; status: recruiting.
02
Drugs
fruquintinib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT06584032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06584032.